According to FutureWise analysis the market for corona virus vaccination and treatment in 2023 is US$ 69.48 billion, and is expected to reach US$ 22.02 billion by 2031 at a CAGR of -13.38%.
Coronaviruses, according to the WHO, are a group of viruses which cause mild illness like common cold or severe levels of illnesses like Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). These viruses are primarily transmitted from animals to humans causing respiratory infections which makes it difficult for patients to breathe. The Middle East Respiratory Syndrome is believed to have transmitted from a particular type of camel to humans while the Severe Acute Respiratory Syndrome is transmitted from civet cats to humans.
There is no defined vaccination that can prevent or treat these viruses, but it is recommended to maintain as much hygiene as possible and to take rest if a patient experiences fever. The recent outbreak in the city of Wuhan, China was initiated from its sea food market. Scientists and doctors were unable to match this virus with known ones and so it was named ‘2019-nCOV’. There is an ongoing research to understand more about the virus, what precautionary measures can be taken, how it affects the patients and what treatments need to be implemented in order to prevent it to spread further anymore.
The Corona Virus Vaccination and Treatment Market is assessed based on factors such as competitive analysis of the progress of emerging players and new entrants, the business expansion policies of key players, the financial and opportunity analysis of market players. Furthermore, the Corona Virus Vaccination and Treatment Market is analysed with respect to the patient type or treatment type, regional segmentation, application spectrum, etc. This research will be conducted with the implementation of latest market research methodologies which shall help organizations understand the overall market scenario and strategize accordingly.